21 CFR 820.30
Design Validation - Risk analysis not performed/inadequate
- Inspections citing it: 5,714
- Of those classified, ended OAI: 26%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 820.30(g)
- 1,689 · Design Validation - Risk analysis not performed/inadequate
- 820.30(i)
- 1,000 · Design changes - Lack of or Inadequate Procedures
- 820.30(a)
- 679 · Design control - no procedures
- 820.30(f)
- 629 · Design verification - Lack of or inadequate procedures
- 820.30(j)
- 471 · Design history file
- 820.30(e)
- 341 · Design review - Lack of or inadequate procedures
- 820.30(c)
- 334 · Design input - documentation
- 820.30(h)
- 228 · Design transfer - Lack of or inadequate procedures
Regulation Text
eCFR did not answer; open it on eCFRRecently Cited Sites
Newest inspections citing this section; each opens the site- DASISIMULATIONS, LLCUnited States · Jan 16, 2026
- Expanse Medical Inc.United States · Jan 15, 2026
- Nuclein LLCUnited States · Jan 13, 2026
- Curative Sound LLCUnited States · Jan 13, 2026
- Innova Vascular IncUnited States · Jan 12, 2026
- ZIIP INCUnited States · Jan 12, 2026
- 4DMedical Ltd.Australia · Jan 8, 2026
- Osseofuse International Inc.United States · Jan 7, 2026
- Peter Schiff EnterprisesUnited States · Dec 31, 2025
- Ashland Specialty Ingredients, G.P.United States · Dec 22, 2025
- Excel Medical Electronics LLCUnited States · Dec 19, 2025
- BioMed Laboratories, LLC.United States · Dec 19, 2025
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR